194 related articles for article (PubMed ID: 37047288)
1. Lysophosphatidylinositol Promotes Chemotaxis and Cytokine Synthesis in Mast Cells with Differential Participation of GPR55 and CB2 Receptors.
Martínez-Aguilar LM; Ibarra-Sánchez A; Guerrero-Morán DJ; Macías-Silva M; Muñoz-Bello JO; Padilla A; Lizano M; González-Espinosa C
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047288
[TBL] [Abstract][Full Text] [Related]
2. Anandamide inhibits FcεRI-dependent degranulation and cytokine synthesis in mast cells through CB
Cruz SL; Sánchez-Miranda E; Castillo-Arellano JI; Cervantes-Villagrana RD; Ibarra-Sánchez A; González-Espinosa C
Int Immunopharmacol; 2018 Nov; 64():298-307. PubMed ID: 30243065
[TBL] [Abstract][Full Text] [Related]
3. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?
Nevalainen T; Irving AJ
Curr Top Med Chem; 2010; 10(8):799-813. PubMed ID: 20370712
[TBL] [Abstract][Full Text] [Related]
4. A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells.
Ford LA; Roelofs AJ; Anavi-Goffer S; Mowat L; Simpson DG; Irving AJ; Rogers MJ; Rajnicek AM; Ross RA
Br J Pharmacol; 2010 Jun; 160(3):762-71. PubMed ID: 20590578
[TBL] [Abstract][Full Text] [Related]
5. Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids.
Anavi-Goffer S; Baillie G; Irving AJ; Gertsch J; Greig IR; Pertwee RG; Ross RA
J Biol Chem; 2012 Jan; 287(1):91-104. PubMed ID: 22027819
[TBL] [Abstract][Full Text] [Related]
6. The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55.
Yamashita A; Oka S; Tanikawa T; Hayashi Y; Nemoto-Sasaki Y; Sugiura T
Prostaglandins Other Lipid Mediat; 2013 Dec; 107():103-16. PubMed ID: 23714700
[TBL] [Abstract][Full Text] [Related]
7. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function.
Kargl J; Brown AJ; Andersen L; Dorn G; Schicho R; Waldhoer M; Heinemann A
J Pharmacol Exp Ther; 2013 Jul; 346(1):54-66. PubMed ID: 23639801
[TBL] [Abstract][Full Text] [Related]
8. The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion.
Kallendrusch S; Kremzow S; Nowicki M; Grabiec U; Winkelmann R; Benz A; Kraft R; Bechmann I; Dehghani F; Koch M
Glia; 2013 Nov; 61(11):1822-31. PubMed ID: 24038453
[TBL] [Abstract][Full Text] [Related]
9. The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity.
Moreno-Navarrete JM; Catalán V; Whyte L; Díaz-Arteaga A; Vázquez-Martínez R; Rotellar F; Guzmán R; Gómez-Ambrosi J; Pulido MR; Russell WR; Imbernón M; Ross RA; Malagón MM; Dieguez C; Fernández-Real JM; Frühbeck G; Nogueiras R
Diabetes; 2012 Feb; 61(2):281-91. PubMed ID: 22179809
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidylinositol causes neurite retraction via GPR55, G13 and RhoA in PC12 cells.
Obara Y; Ueno S; Yanagihata Y; Nakahata N
PLoS One; 2011; 6(8):e24284. PubMed ID: 21904624
[TBL] [Abstract][Full Text] [Related]
11. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.
Kapur A; Zhao P; Sharir H; Bai Y; Caron MG; Barak LS; Abood ME
J Biol Chem; 2009 Oct; 284(43):29817-27. PubMed ID: 19723626
[TBL] [Abstract][Full Text] [Related]
12. Glycerophosphodiesterase 3 (GDE3) is a lysophosphatidylinositol-specific ectophospholipase C acting as an endocannabinoid signaling switch.
Briand-Mésange F; Pons V; Allart S; Masquelier J; Chicanne G; Beton N; Payrastre B; Muccioli GG; Ausseil J; Davignon JL; Salles JP; Chap H
J Biol Chem; 2020 Nov; 295(46):15767-15781. PubMed ID: 32917725
[TBL] [Abstract][Full Text] [Related]
13. GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells.
Bondarenko A; Waldeck-Weiermair M; Naghdi S; Poteser M; Malli R; Graier WF
Br J Pharmacol; 2010 Sep; 161(2):308-20. PubMed ID: 20735417
[TBL] [Abstract][Full Text] [Related]
14. Modulation of l-α-lysophosphatidylinositol/GPR55 MAP kinase signalling by CB2 receptor agonists: identifying novel GPR55 inhibitors.
Anavi-Goffer S; Irving AJ; Ross RA
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):303-10. PubMed ID: 27089417
[TBL] [Abstract][Full Text] [Related]
15. Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells.
Oka S; Kimura S; Toshida T; Ota R; Yamashita A; Sugiura T
J Biochem; 2010 May; 147(5):671-8. PubMed ID: 20051382
[TBL] [Abstract][Full Text] [Related]
16. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo.
Whyte LS; Ryberg E; Sims NA; Ridge SA; Mackie K; Greasley PJ; Ross RA; Rogers MJ
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16511-6. PubMed ID: 19805329
[TBL] [Abstract][Full Text] [Related]
17. l-α-Lysophosphatidylinositol (LPI) aggravates myocardial ischemia/reperfusion injury via a GPR55/ROCK-dependent pathway.
Robertson-Gray OJ; Walsh SK; Ryberg E; Jönsson-Rylander AC; Lipina C; Wainwright CL
Pharmacol Res Perspect; 2019 Jun; 7(3):e00487. PubMed ID: 31149342
[TBL] [Abstract][Full Text] [Related]
18. The oncogenic lysophosphatidylinositol (LPI)/GPR55 signaling.
Calvillo-Robledo A; Cervantes-Villagrana RD; Morales P; Marichal-Cancino BA
Life Sci; 2022 Jul; 301():120596. PubMed ID: 35500681
[TBL] [Abstract][Full Text] [Related]
19. Analysis of anandamide- and lysophosphatidylinositol-induced inhibition of the vasopressor responses produced by sympathetic stimulation or noradrenaline in pithed rats.
Marichal-Cancino BA; Manrique-Maldonado G; Altamirano-Espinoza AH; Ruiz-Salinas I; González-Hernández A; Maassenvandenbrink A; Villalón CM
Eur J Pharmacol; 2013 Dec; 721(1-3):168-77. PubMed ID: 24076186
[TBL] [Abstract][Full Text] [Related]
20. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.
Sharir H; Console-Bram L; Mundy C; Popoff SN; Kapur A; Abood ME
J Neuroimmune Pharmacol; 2012 Dec; 7(4):856-65. PubMed ID: 22454039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
